Novo Nordisk and Eli Lilly are positioning themselves to capture the GLP-1 pill market as Medicare coverage decisions loom. The two pharmaceutical giants have spent years battling over injectable GLP-1 drugs like Novo's Ozempic and Wegovy and Lilly's Mounjaro, which treat diabetes and weight loss. Now both companies are readying oral versions of these blockbuster medications for seniors.
The shift to pills matters for Medicare beneficiaries. Injections require weekly or monthly dosing and needles, while pills offer convenience and simplicity. Seniors already taking GLP-1 injections could switch to tablets if coverage becomes available. For those hesitant about needles, oral options remove a major barrier to access.
Novo Nordisk is developing rybelsus, an oral semaglutide tablet approved for diabetes. The company plans to expand its use for weight loss. Eli Lilly works on tirzepatide, an oral version of its dual-action GLP-1 drug, with weight-loss applications in development.
Medicare coverage decisions will reshape the competitive landscape. The Centers for Medicare and Medicaid Services has been cautious about covering weight-loss medications, typically reserving coverage for diabetes treatment. However, growing evidence of cardiovascular benefits from GLP-1 drugs may influence policy. Whichever company wins favorable Medicare terms first gains access to roughly 45 million seniors, many with both diabetes and obesity.
Pricing strategy becomes critical. Medicare Part D plans negotiate drug costs, but oral formulations sometimes command different price points than injectables. Novo and Lilly will need to balance profitability with accessibility to seniors on fixed incomes.
The pill competition reflects broader industry trends. Oral medications typically see higher patient compliance rates than injections. Both companies recognize that capturing the pill